



三顧股份有限公司
METATECH (AP) INC.

Stock Code **3224**



METATECH (AP) INC.

2026 Investor Conference

2026/10/15



Disclaimer


The contents of this presentation and related information are the information collected by the company from various prior documents.

The Company is dedicated to the future development. The actual results of operations, financial condition and business achievement may differ from the forecasted information. This may be due to risk factors that are not expected to be captured by market conditions.

The future development described in this presentation is based on the judgment of market information and the development of the Group's business strategy. The Company is not responsible for alerting or updating for future development as it may be adjusted with the market trend.

Governance Evaluation Score Distribution of OTC Company

Stable Corporate Governance




Revenue Performance

2023 ~ 2026Q2


Electronics Business Group

Unit: NT\$ thousands




Biomedical Business Group

Unit: NT\$ thousands




Net Assets

Unit: NT\$ thousands



Profit and Loss

Unit: NT\$ thousands



Agenda

1

**Electronics Business Group:
Status & Market Strategy**

2

**Biomedical Business Group:
Status & Market Strategy**

01.


Electronics Business Group: Status & Market Strategy

AI Market Applications and
Strategic Goals




Electronics Business: Three-Year Performance and Revenue Mix

2023 ~ 2025



Key Growth Markets

Strong demand for high-end AI servers is driving overall revenue growth. This is our key market for further investment and expansion.




Other Markets

AI power supplies and networking switches are growing at a similar pace. AI storage remains steady, while semiconductors make up a smaller share of revenue.

	2023	2024	2025
AI Servers	15.0%	18.0%	23.3%
AI Power Supplies	5.0%	6.0%	8.0%
AI Networking Switches	5.0%	6.0%	8.0%
AI Storage	6.0%	6.0%	7.0%
Semiconductors	1.0%	1.0%	1.3%
Others	68.0%	63.0%	52.4%

Our business mix is moving toward
“A stronger focus on AI and higher
value-added products”

Revenue Mix Outlook



	2026(F)	2027(F)
AI Servers	27.0%	28.0%
AI Power Supplies	15.0%	15.0%
AI Networking Switches	10.0%	12.0%
AI Storage	9.0%	9.0%
Semiconductors	6.5%	9.0%
Others	32.5%	27.0%

2027 Outlook and Market Strategy



Core Markets

AI servers: Applications using GPUs, CPUs and ASICs are expected to drive growth 2027.

AI power supplies: Demand for products rated above 1,000 W is expected to drive growth 2027.



Growth Opportunities

Networking switches and semiconductors offer strong growth potential, especially co-packaged optics (CPO) and co-packaged copper (CPC) for high-speed connections. AI computing and data centers are driving demand for greater bandwidth and lower power consumption.


MetaTech matches customer needs with upstream product solutions. We provide end-to-end support from design to delivery to capture these growth opportunities.

02.

Biomedical Business Group: Status & Market Strategy



Increasingly Stringent Serum Quality Requirements



FBS vs. hPL under New Rules

Item	Current FBS (fetal bovine serum)	Gamma-irradiated FBS	hPL (human platelet lysate)
Source classification	Animal-derived	Animal-derived	Human-derived (non-animal)
2028 requirements	Viral inactivation/removal evidence required; hard to meet today	Can meet the "viral inactivation step" requirement	Still requires adventitious-agent safety evidence and viral-clearance assessment for human-derived reagents
Long-term regulatory risk	High: global trend is to phase out animal components	Medium: still animal-derived; may be required to replace again	Low: aligned with the international "animal-free" direction
Adoption cost	—	Process change + validation once, possibly again later	Process change + validation once, done

MetaTech × ZHENG YANG Partnership



hPL Supplement (Human Platelet Lysate Culture Supplement) — From GMP Manufacturing to the Cell Culture Bench



MetaTech

GMP Manufacturing

- GMP manufacturing & quality management
- Batch release & stable supply
- Process technology & scale-up

Make
Supply



Sell
Promote



ZHENG YANG

Sales & Market Promotion

- Channel build-out & sales
- Outreach to cell therapy companies & research institutes
- Technical support & market feedback



MetaTech GMP
Manufacturing



QC Release



ZHENG YANG
Sales and
Promotion



Cell Therapy
& Research



Cell Culture

From key raw-material technology to clinical products and commercial manufacturing

ZHENG YANG 's technology / products / markets × MetaTech's GMP plant / CMO / clinical industrialization platform



» Core technology & licensing base, global expansion «

MetaTech provides
“GMP + CMO + Clinical” platform




ZHENG YANG provides
“Technology + Product + Market” entry

Together accelerating regenerative medicine products from
R&D and clinical to commercialization

Global hPL Market Size

Market Research Future



Existing Markets → Global Expansion

Building on existing shipment markets and extending into high-growth regions



MetaTech takes on GMP-grade manufacturing as commercial cell therapy grows



Clinical Grade hPL


- ✓ High-margin core product
- ✓ Rising revenue share



Existing Customer Transition

- ✓ Global customer transition
- ✓ Growing penetration

Growth Path



Innovative global biologic, made locally by MetaTech for Taiwan's dry eye market

An international dry eye biologic has entered **Phase III**. Combining ZHENG YANG's international product and technology footprint with MetaTech's GMP manufacturing capability, Elate Ocular will be brought to Taiwan's dry eye market, creating partnership value from clinical supply to commercial manufacturing

1 Cambium Bio with ZHENG YANG / Elate Ocular® Innovative international biologic with major market potential

Elate Ocular®

A biologic for moderate-to-severe dry eye disease

> US\$2B

US dry eye prescription drug market¹

17M

Diagnosed adult patients¹

FDA Fast Track

Potential first-in-class biologic¹

Phase III (CAMOMILE 2)

Up to 515 subjects, randomized, double-blind, controlled²

FDA confirmed

A single pivotal Phase 3 trial can form part of the BLA pathway³

2 Taiwan Dry Eye Market

Stable demand driven by high prevalence and an aging population

7.85%

Dry eye prevalence in Taiwan⁴

Female 10.49%

Male 4.92%

20.72%

Prevalence, age 65+⁴

Another study shows

Age 65+ 33.7%⁵

~ 1.8M

Potential patients in Taiwan⁶

(2026 population × 7.85% prevalence)

~ US\$100M

2025 Taiwan dry eye drug market size⁷

2030 ~US\$140M

2033 ~US\$170M

3 MetaTech X ZHENG YANG

Elate Ocular® made in Taiwan, creating long-term value



Global Clinical Development
Elate Ocular®



ZHENG YANG
BIOMEDICAL TECHNOLOGY CO., LTD.

Taiwan Entry



三 | 顧 | 生 | 醫
MetaTech BIOMED

Taiwan PIC/S GMP
Clinical → commercial



Value for MetaTech Biomedical



Local manufacturing of a global innovative product

Elate Ocular® Taiwan PIC/S GMP manufacturing



Clinical supply capability

Supply for Taiwan clinical trials & registration



Commercial manufacturing platform

Expanded commercial supply after Taiwan approval



From CMO to product-based revenue

Taiwan industrialization of a global innovative drug

1. Cambium Bio. Corporate Presentation. U.dry eye market -US\$28 annual prescription expenditure: ~1M diagnosed adults; Fast Trackiro

2. Cambium Bio. CAM-101-002 (CAMOMILE 2) Clinical Study Protocol V2.0, May 29, 2026. Phase up to 515 subjects.

3. Cambium Bio. Corporate Presentation. FDA agreement on single pivotal Phase 3 trial as part of BLA pathway.

4. Lin PY, et al. Prevalence of dry eye disease in Taiwan: a population-based study. Ophthalmology, 2021.


5. Lin HC, et al. Prevalence of dry eye among elderly in Taiwan. Ophthalmic Epidemiology, 2003.

6. Ministry of the Interior, Taiwan. Household-registered population as of June 2026: 23,243,565; at 7.85% prevalence ≈ 1,825,000 patients

7. Reports insights. Taiwan Eye Drop Market - Eye Sundrome Segment. 2025: -US\$100M; 2030: -US\$140M; 2033: -US\$170M.

One GMP/CMO platform for diverse regenerative products

Turning existing products and technology entry points into scalable manufacturing demand for MetaTech



Value

Expanding MetaTech Biomedical's CMO scope, linking “raw-material technology
→ product → clinical → commercialization”

Precision Medicine Starts with iPSC Banking



2010 CiRA Lab established

2013 REPROCELL (private) | 2025 my iPS Factory

 National
Institute of Health
2012 Korea National Stem
Cell Bank


EBiSC

2014 EU EBiSC established


CIRM
CALIFORNIA'S STEM CELL AGENCY


FUJIFILM
Cellular
Dynamics

2013 US CIRM launched

- 2024 Taiwan's No. 1 personal iPSC bank
- Taiwan's largest private bank


MetaTech



Category	Indication	Product / Cells	Institution / Company (Country)	Stage
Approved	Severe heart failure	RiHEART (allogeneic iPSC cardiomyocyte sheet)	Osaka Univ. Yoshiki Sawa / Cuorips (Japan)	Conditional, time-limited approval Mar 6, 2026; approval valid until Mar 2033
	Parkinson’ s disease	AMCHEPRY (allogeneic iPSC dopaminergic progenitor cells; raguneprocel)	Kyoto Univ. / Sumitomo Pharma · RACTHERA (Japan)	Conditional, time-limited approval Mar 6, 2026; world’ s first iPSC Parkinson’ s product
Filed	Heart failure	HS-001 (allogeneic iPSC cardiac spheroids)	Heartseed + Novo Nordisk (Japan)	Phase 1/2 (n=10) completed → preparing approval application
	Limbal stem cell deficiency	REM-01 (iPSC corneal epithelial sheet)	Osaka Univ. Kohji Nishida / Raymei (Japan)	Company-sponsored Phase 2 (n=12)
In clinical trials (iPSC)	Retina (RPE dysfunction / AMD)	iPSC-RPE aggregates; MastCT-03	RIKEN / Kobe Eye Center Masayo Takahashi / VCCT (Japan)	Clinical research
	Type 1 diabetes	OZTx-410 (allogeneic iPSC islet cell sheet)	Kyoto Univ. / Orizuru Therapeutics (Japan)	Investigator-initiated trial (first-in-human)
	Spinal cord injury	iPSC neural progenitor cells (KP8011)	Keio Univ. Hideyuki Okano / Masaya Nakamura / K Pharma (Japan)	Clinical research completed → 2027 company-sponsored trial
	Lupus nephritis (autoimmune)	FT819 (iPSC CAR-T)	Fate Therapeutics (USA)	Phase 2
	Knee cartilage / platelets	iPSC cartilage; iPSC platelets (MEG-002)	Kyoto Univ. Noriyuki Tsumaki / Arktus; Kyoto Univ. Koji Eto / Megakaryon (Japan)	Non-clinical (GLP) / Phase 1/2 stalled

Sources: Cuorips / Nikkei Sep 30, 2026 · Nikkei Biotech Jul 22, 2026; Sumitomo Pharma earnings briefing Jul 31, 2026; Heartseed ESC 2026 press release (Aug 31, 2026); jRCT; Keio Univ. press release Jul 22, 2026; Nature Medicine 2026; Fate Therapeutics press releases Sep 9 & 25, 2026; Raymei; CiRA Foundation; Nikkei Biotech (updated through Oct 5, 2026)



三顧股份有限公司
METATECH (AP) INC.

Stock Code **3224**

Thank You



三顧股份有限公司
METATECH (AP) INC.

Stock Code **3224**

Q & A